Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M48,980Revenue $M6,022Net Margin (%)58.6Altman Z-Score4.4
Enterprise Value $M50,243EPS $17.3Operating Margin %30.4Piotroski F-Score5
P/E(ttm)13.6Beneish M-Score-2.9Pre-tax Margin (%)57.4Higher ROA y-yY
Price/Book5.210-y EBITDA Growth Rate %--Quick Ratio0.4Cash flow > EarningsY
Price/Sales7.85-y EBITDA Growth Rate %27.4Current Ratio0.5Lower Leverage y-yY
Price/Free Cash Flow12.6y-y EBITDA Growth Rate %79.7ROA % (ttm)27.7Higher Current Ratio y-yN
Dividend Yield %0.3PEG0.5ROE % (ttm)50.2Less Shares Outstanding y-yN
Payout Ratio %4.0Shares Outstanding M200ROIC % (ttm)24.1Gross Margin Increase y-yN

Gurus Latest Trades with SHPG

Number of guru portfolios checked: 68.
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SHPGFirst Eagle Investment 2015-03-31 Add0.12%$205.66 - $253.64
($229.81)
$ 244.787%Add 254.93%294,539
SHPGLeon Cooperman 2015-03-31 Add0.1%$205.66 - $253.64
($229.81)
$ 244.787%Add 5.70%500,192
SHPGMario Gabelli 2015-03-31 Sold Out -0.018%$205.66 - $253.64
($229.81)
$ 244.787%Sold Out0
SHPGKen Fisher 2015-03-31 Add$205.66 - $253.64
($229.81)
$ 244.787%Add 1.35%14,791
SHPGLeon Cooperman 2014-12-31 Buy 1.7%$170.49 - $262.71
($211.39)
$ 244.7816%New holding473,237
SHPGJohn Paulson 2014-12-31 Reduce-0.77%$170.49 - $262.71
($211.41)
$ 244.7816%Reduce 7.93%8,328,304
SHPGDavid Tepper 2014-12-31 Sold Out -0.71%$170.49 - $262.71
($211.58)
$ 244.7816%Sold Out0
SHPGFirst Eagle Investment 2014-12-31 Add0.04%$170.49 - $262.71
($211.58)
$ 244.7816%Add 453.24%82,986
SHPGMario Gabelli 2014-12-31 Reduce-0.03%$170.49 - $262.71
($211.58)
$ 244.7816%Reduce 57.13%16,225
SHPGKen Fisher 2014-12-31 Add0.01%$170.49 - $262.71
($211.58)
$ 244.7816%Add 416.24%14,594
SHPGJohn Paulson 2014-09-30 Add6.09%$231.98 - $262.64
($248.14)
$ 244.78-1%Add 168.70%9,046,000
SHPGDavid Tepper 2014-09-30 Buy 0.71%$231.98 - $262.64
($248.14)
$ 244.78-1%New holding185,944
SHPGMario Gabelli 2014-09-30 Buy 0.05%$231.98 - $262.64
($248.14)
$ 244.78-1%New holding37,850
SHPGFirst Eagle Investment 2014-09-30 Buy 0.01%$231.98 - $262.64
($248.14)
$ 244.78-1%New holding15,000
SHPGKen Fisher 2014-09-30 Reduce$231.98 - $262.64
($248.14)
$ 244.78-1%Reduce 39.56%2,827
SHPGJohn Paulson 2014-06-30 Add0.84%$142.83 - $234.98
($172.9)
$ 244.7842%Add 33.07%3,366,539
SHPGKen Fisher 2014-06-30 Add$142.83 - $234.98
($172.9)
$ 244.7842%Add 91.13%4,677
SHPGJohn Paulson 2013-12-31 Reduce-0.24%$113.87 - $140.87
($131.38)
$ 244.7886%Reduce 11.03%2,529,854
SHPGJohn Paulson 2013-06-30 Add0.98%$86.59 - $99.85
($93.74)
$ 244.78161%Add 107.43%2,843,500
SHPGMario Gabelli 2013-03-31 Sold Out -0.003%$89.83 - $101.63
($95.88)
$ 244.78155%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SHPG is held by these investors:

Premium Most recent portfolio changes are included for Premium Members only!


SHPG: Insider Buys/Sells

Click Here for All Insider Trades.

No Insider Trades Found!

Quarterly/Annual Reports about SHPG:

News about SHPG:

Articles On GuruFocus.com
Invesco European Growth Fund Parts With Two Stakes Jul 01 2015 
Andreas Halvorsen Increases Stake in Esperion Therapeutics Jun 29 2015 
Smart Guru John Paulson Bullish on Actavis Jun 18 2015 
8 Top Healthcare Stocks to Watch May 13 2015 
John Paulson's Stocks Trading at Low P/E May 04 2015 
Shire Reports A Good Quarter Promoted By Drug Sales May 03 2015 
Top Stock Picks Among Companies That Recently Increased Dividends Mar 09 2015 
AbbVie To Acquire Biopharmaceutical Firm Pharmacyclics Mar 06 2015 
Valeant Pharmaceuticals Finally Zeros In On Salix Pharmaceuticals Feb 24 2015 
Three Pharma Majors In The Run To Acquire Salix Feb 16 2015 

More From Other Websites
Are Patent Challenges Paying Off For Kyle Bass? Jul 06 2015
Invesco European Growth Fund Parts With Two Stakes Jul 01 2015
SHIRE PLC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jul 01 2015
Shire Launches Spotlight on Gaucher Film Contest and Calls for Video Entries Sharing Experiences of... Jul 01 2015
Is SkyePharma PLC A Better Buy Than Shire PLC Or Hikma Pharmaceuticals Plc? Jun 25 2015
SHIRE PLC Files SEC form 8-K/A, Financial Statements and Exhibits Jun 22 2015
Is ReNeuron Group Plc The Perfect Partner For BTG plc And Shire PLC In Your Portfolio? Jun 22 2015
American Adults Surpass Children in Taking Drugs to Stay Focused Jun 22 2015
More Adults Than Kids Now Take Attention-Deficit Drugs in U.S. Jun 22 2015
SHIRE PLC Files SEC form 8-K, Financial Statements and Exhibits Jun 18 2015
Shire to Make Milestone Payment to ArmaGen for AGT-182 - Analyst Blog Jun 16 2015
“Buy High, Sell Higher”: A Look At Shire plc, ITV plc, Sirius Minerals plc, Betfair Group Ltd &... Jun 15 2015
ArmaGen Achieves Clinical Milestone in Hunter Syndrome Collaboration with Shire Jun 15 2015
Shire Names Bill Mordan General Counsel and Corporate Secretary; Appoints Michele Galen Head of... Jun 15 2015
SHIRE PLC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and... Jun 11 2015
Shire Appoints Olivier Bohuon to its Board of Directors Jun 11 2015
Shire Watches Dyax Threat to $630,000 Orphan Drug Jun 10 2015
Stock Pops & Drops: SHPG, DB, AMBA & INVN Jun 08 2015
Actelion Could Give Shire Heartburn Jun 08 2015

Add Notes, Comments

If you want to ask a question, or report a bug, please create a support ticket.

User Comments

No comment yet
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK